Top

Cost Effectiveness and Resource Allocation

Published in:

Open Access 01-12-2008 | Research

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Authors: Harrell W Chesson, Dayne Collins, Kathryn Koski

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2008

Abstract

Background

Sexually transmitted infection (STI) prevention programs can mitigate the health and economic burden of STIs. A tool to estimate the economic benefits of STI programs could prove useful to STI program personnel.

Methods

We developed formulas that can be applied to estimate the direct medical costs and indirect costs (lost productivity) averted by STI programs in the United States. Costs and probabilities for these formulas were based primarily on published studies.

Results

We present a series of formulas that can be used to estimate the economic benefits of STI prevention (in 2006 US dollars), using data routinely collected by STI programs. For example, the averted sequelae costs associated with treating women for chlamydia is given as (C_w)(0.16)(0.925)(0.70)($1,995), where C_w is the number of infected women treated for chlamydia, 0.16 is the absolute reduction in the probability of pelvic inflammatory disease (PID) as a result of treatment, 0.925 is an adjustment factor to prevent double-counting of PID averted in women with both chlamydia and gonorrhea, 0.70 is an adjustment factor to account for the possibility of re-infection, and $1,995 is the average cost per case of PID, based on published sources.

Conclusion

The formulas developed in this study can be a useful tool for STI program personnel to generate evidence-based estimates of the economic impact of their program and can facilitate the assessment of the cost-effectiveness of their activities.

Chesson HW, Gift TL, Pulver ALS: The economic value of reductions in gonorrhea and syphilis incidence in the United States, 1990–2003. Prev Med 2006, 43: 411–415. 10.1016/j.ypmed.2006.06.013PubMedCrossRef

Weinstock H, Berman S, Cates Jr. W: Sexually transmitted diseases in American youth: incidence and prevalence estimates. Perspect Sex Reprod Health 2004, 36: 6–10. 10.1363/3600604PubMedCrossRef

Siegel JE: Estimates of the economic burden of STDs: Review of the literature with updates. In The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Edited by: Eng TR and Butler WT. Washington, DC, National Academy Press; 1997:330–356.

Association ASH: Sexually Transmitted Diseases in America: How Many Cases and at What Cost?. Edited by: Alexander LL, Cates JR, Herndon N and Ratcliffe JF. Menlo Park, CA, Kaiser Family Foundation; 1998.

Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL: The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004, 36: 11–19. 10.1363/3601104PubMedCrossRef

Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, Kellerman SE: The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006, 43: 451–457. 10.1097/01.qai.0000243090.32866.4ePubMedCrossRef

Control CD: Cost-benefit ratios of prevention. In STD-HIV Interchange. Atlanta, GA, Centers for Disease Control; 1992.

Gold MR, Siegal JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. Edited by: Gold MR, Siegal JE, Russell LB and Weinstein MC. New York, Oxford University Press; 1996.

Haddix AC, Teutsch SM, Corso PS: Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. 2nd edition. Edited by: Haddix AC, Teutsch SM and Corso PS. New York, Oxford University Press; 2002.

10.

Washington AE, Johnson RE, Sanders LL Jr.: Chlamydia trachomatis infections in the United States: what are they costing us? JAMA 1987, 257: 2070–2072. 10.1001/jama.257.15.2070PubMedCrossRef

11.

Tait IA, Duthie SJ, Taylor-Robinson D: Silent upper genital tract chlamydia infection and disease in women. Int J STD AIDS 1997, 8: 329–331. 10.1258/0956462971920037PubMedCrossRef

12.

Recommendations for the prevention and management of Chlamydia trachomatis infections, 1993. Centers for Disease Control and Prevention. MMWR Recomm Rep 1993,42(RR-12):1–39.

13.

Rees E: The treatment of pelvic inflammatory disease. Am J Obstet Gynecol 1980, 138: 1042–1047.PubMed

14.

Douglas JM Jr., Newman D, Bolan G, Zenilman JM, Rogers J, Rhodes F, Kamb M, Peterman T: Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection. Int J STD AIDS 2001, 12: 65–67. 10.1258/0956462011916659CrossRef

15.

Haddix AC, Hillis SD, Kassler WJ: The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995, 22: 274–280.PubMedCrossRef

16.

Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, Sweet RL: Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002, 100: 456–463. 10.1016/S0029-7844(02)02118-XPubMedCrossRef

17.

Hook EW III, Spitters C, Reichart CA, Neumann TM, Quinn TC: Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA 1994, 272: 867–870. 10.1001/jama.272.11.867PubMedCrossRef

18.

Bachmann L, Richey CM, Waites K, Schwebke JR, Hook EW III: Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center. Sex Transm Dis 1999, 26: 496–499. 10.1097/00007435-199910000-00002PubMedCrossRef

19.

Westrom L, Eschenbach D: Pelvic inflammatory disease. In Sexually Transmitted Diseases. Volume 58. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:783–809.

20.

Gutman LT: Gonococcal diseases in infants and children. In Sexually Transmitted Diseases. Volume 82. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1145–1153.

21.

Marrazzo JM, Celum CL, White C, Handsfield HH: Cost-effectiveness of urine-based screening for Chlamydia trachomatis with ligase chain reaction in asymptomatic males. In Proceedings of the 13th Meeting of the International Society for Sexually Transmitted Disease Research. Denver, CO; 1999.

22.

Magid D, Douglas JM Jr., Schwartz JS: Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Int Med 1996, 124: 389–399.PubMedCrossRef

23.

Rein DB, Kassler WJ, Irwin KL, Rabiee L: Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000, 95: 397–402. 10.1016/S0029-7844(99)00551-7PubMed

24.

Yeh JM, Hook EW III, Goldie SJ: A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003, 30: 369–378. 10.1097/00007435-200305000-00001PubMedCrossRef

25.

Rein DB, Gift TL: A refined estimate of the lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2004, 31: 325. 10.1097/00007435-200405000-00013PubMedCrossRef

26.

Gift TL, Owens CJ: The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims. Sex Transm Dis 2006, 33: S84-S88. 10.1097/01.olq.0000235149.41948.faPubMedCrossRef

27.

Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55: 1–94.

28.

Wasserheit JN, Valdiserri RO, Wood RW: Assessment of STD/HIV prevention programs in the United States: national, local, and community perspectives. In Sexually Transmitted Diseases. Volume 90. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1255–1271.

29.

Singh AE, Romanowski B: Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev 1999, 12: 187–209.PubMedCentralPubMed

30.

Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL: Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 2004, 190: 1004–1010. 10.1016/j.ajog.2004.02.015PubMedCrossRef

31.

Finelli L, Nakashima AK, Hillis S, Crayne E, Spitalny KC: Selective screening versus presumptive treatment criteria for identification of women with chlamydial infection in public clinics: New Jersey. Am J Obstet Gynecol 1996, 174: 1527–1533. 10.1016/S0002-9378(96)70601-4PubMedCrossRef

32.

Ryan CA, Courtois BN, Hawes SE, Stevens CE, Eschenbach DA, Holmes KK: Risk assessment, symptoms, and signs as predictors of vulvovaginal and cervical infections in an urban US STD clinic: implications for use of STD algorithms. Sex Transm Infect 1998, 74 Suppl 1: S59-S76.PubMed

33.

DiCarlo RP, Martin DH: The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997, 25: 292–298. 10.1086/514548PubMedCrossRef

34.

Khan A, Fortenberry JD, Juliar BE, Tu W, Orr DP, Batteiger BE: The prevalence of chlamydia, gonorrhea, and trichomonas in sexual partnerships: implications for partner notification and treatment. Sex Transm Dis 2005, 32: 260–264. 10.1097/01.olq.0000161089.53411.cbPubMedCentralPubMedCrossRef

35.

Rothenberg RB, Potterat JJ: Partner notification for sexually transmitted disease and HIV infection. In Sexually Transmitted Diseases. Volume 55. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:745–752.

36.

Ruden AK, Jonsson A, Lidbrink P, Allebeck P, Bygdeman SM: Endemic versus non-endemic gonorrhoea in Stockholm: results of contact tracing. Int J STD AIDS 1993, 4: 284–292.PubMed

37.

Samoff E, Koumans EH, Katkowsky S, Shouse RL, Markowitz LE: Contact-tracing outcomes among male syphilis patients in Fulton County, Georgia, 2003. Sex Transm Dis 2007, 34: 456–460.PubMed

38.

Gunn RA, Montes JM, Toomey KE, Rolfs RT, Greenspan JR, Spitters CE, Waterman SH: Syphilis in San Diego County 1983–1992: crack cocaine, prostitution, and the limitations of partner notification. Sex Transm Dis 1995, 22: 60–66.PubMedCrossRef

39.

Engelgau MM, Woernle CH, Rolfs RT, Greenspan JR, O'Cain M, Gorsky RD: Control of epidemic early syphilis: the results of an intervention campaign using social networks. Sex Transm Dis 1995, 22: 203–209.PubMedCrossRef

40.

Sparling PF: Natural history of syphilis. In Sexually Transmitted Diseases. Volume 34. Third edition. Edited by: Holmes KK, Sparling PF, Mardh P, Lemon SE, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:473–478.

41.

Schroeter AL, Turner RH, Lucas JB, Brown WJ: Therapy for incubating syphilis. Effectiveness of gonorrhea treatment. JAMA 1971, 218: 711–713. 10.1001/jama.218.5.711PubMedCrossRef

42.

Lyss SB, Kamb ML, Peterman TA, Moran JS, Newman DR, Bolan G, Douglas JM Jr., Iatesta M, Malotte CK, Zenilman JM, Ehret J, Gaydos C, Newhall WJ: Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med 2003, 139: 178–185.PubMedCrossRef

43.

Creighton S, Tenant-Flowers M, Taylor CB, Miller R, Low N: Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean? Int J STD AIDS 2003, 14: 109–113. 10.1258/095646203321156872PubMedCrossRef

44.

Levitt MA, Johnson S, Engelstad L, Montana R, Stewart S: Clinical management of chlamydia and gonorrhea infection in a county teaching emergency department--concerns in overtreatment, undertreatment, and follow-up treatment success. J Emerg Med 2003, 25: 7–11. 10.1016/S0736-4679(03)00131-8PubMedCrossRef

45.

Lifson AR, Halcon LL, Hannan P, St LME, Hayman CR: Screening for sexually transmitted infections among economically disadvantaged youth in a national job training program. J Adolesc Health 2001, 28: 190–196. 10.1016/S1054-139X(00)00165-8PubMedCrossRef

46.

Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, Cohen MS, Harris KM, Udry JR: Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291: 2229–2236. 10.1001/jama.291.18.2229PubMedCrossRef

47.

Bachmann LH, Pigott D, Desmond R, Jones M, Lumpkins J, Gala P, Terndrup T, Hook EW III: Prevalence and factors associated with gonorrhea and chlamydial infection in at-risk females presenting to an urban emergency department. Sex Transm Dis 2003, 30: 335–339. 10.1097/00007435-200304000-00012PubMedCrossRef

48.

Nsuami M, Cammarata CL, Brooks BN, Taylor SN, Martin DH: Chlamydia and gonorrhea co-occurrence in a high school population. Sex Transm Dis 2004, 31: 424–427. 10.1097/01.OLQ.0000130535.96576.D3PubMedCrossRef

49.

Dicker LW, Mosure DJ, Berman SM, Levine WC: Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000. Sex Transm Dis 2003, 30: 472–476. 10.1097/00007435-200305000-00016PubMedCrossRef

50.

Whittington WL, Kent C, Kissinger P, Oh MK, Fortenberry JD, Hillis SE, Litchfield B, Bolan GA, St Louis ME, Farley TA, Handsfield HH: Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001, 28: 117–123. 10.1097/00007435-200102000-00011PubMedCrossRef

51.

Richey CM, Macaluso M, Hook EW: Determinants of reinfection with Chlamydia trachomatis. Sex Transm Dis 1999, 26: 4–11. 10.1097/00007435-199901000-00002PubMedCrossRef

52.

Bernstein KT, Zenilman J, Olthoff G, Marsiglia VC, Erbelding EJ: Gonorrhea reinfection among sexually transmitted disease clinic attendees in Baltimore, Maryland. Sex Transm Dis 2006, 33: 80–86. 10.1097/01.olq.0000187233.53622.8aPubMedCrossRef

53.

Schillinger JA, Kissinger P, Calvet H, Whittington WL, Ransom RL, Sternberg MR, Berman SM, Kent CK, Martin DH, Oh MK, Handsfield HH, Bolan G, Markowitz LE, Fortenberry JD: Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003, 30: 49–56. 10.1097/00007435-200301000-00011PubMedCrossRef

54.

Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, Clark A, Malinski C, Helmers JR, Thomas KK, Holmes KK: Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352: 676–685. 10.1056/NEJMoa041681PubMedCrossRef

55.

Chamot E, Coughlin SS, Farley TA, Rice JC: Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases. AIDS 1999, 13: 971–979. 10.1097/00002030-199905280-00014PubMedCrossRef

56.

Ellen JM, Hessol NA, Kohn RP, Bolan GA: An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989–1993: evidence for core groups. J Infect Dis 1997, 175: 1519–1522.PubMedCrossRef

57.

Fortenberry JD, Brizendine EJ, Katz BP, Wools KK, Blythe MJ, Orr DP: Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. Sex Transm Dis 1999, 26: 26–32. 10.1097/00007435-199901000-00005PubMedCrossRef

58.

Gunn RA, Maroufi A, Fox KK, Berman SM: Surveillance for repeat gonorrhea infection, San Diego, California, 1995–2001: establishing definitions and methods. Sex Transm Dis 2004, 31: 373–379. 10.1097/00007435-200406000-00011PubMedCrossRef

59.

Gunn RA, Fitzgerald S, Aral SO: Sexually transmitted disease clinic clients at risk for subsequent gonorrhea and chlamydia infections: possible 'core' transmitters. Sex Transm Dis 2000, 27: 343–349. 10.1097/00007435-200007000-00008PubMedCrossRef

60.

Oh MK, Cloud GA, Fleenor M, Sturdevant MS, Nesmith JD, Feinstein RA: Risk for gonococcal and chlamydial cervicitis in adolescent females: incidence and recurrence in a prospective cohort study. J Adolesc Health 1996, 18: 270–275. 10.1016/1054-139X(95)00232-HPubMedCrossRef

61.

Orr DP, Johnston K, Brizendine E, Katz B, Fortenberry JD: Subsequent sexually transmitted infection in urban adolescents and young adults. Arch Pediatr Adolesc Med 2001, 155: 947–953.PubMedCrossRef

62.

Thomas JC, Weiner DH, Schoenbach VJ, Earp JA: Frequent re-infection in a community with hyperendemic gonorrhoea and chlamydia: appropriate clinical actions. Int J STD AIDS 2000, 11: 461–467. 10.1258/0956462001916254PubMedCrossRef

63.

Radolf JD, Sanchez PJ, Schulz KF, Murphy FK: Congenital syphilis. In Sexually Transmitted Diseases. Volume 84. Third edition. Edited by: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P and Wasserheit JN. New York, McGraw-Hill; 1999:1165–1189.

64.

de Lissovoy G, Zenilman J, Nelson KE, Ahmed F, Celentano DD: The cost of a preventable disease: estimated U.S. national medical expenditures for congenital syphilis, 1990. Public Health Rep 1995, 110: 403–409.PubMedCentralPubMed

65.

Bateman DA, Phibbs CS, Joyce T, Heagarty MC: The hospital cost of congenital syphilis. J Pediatr 1997, 130: 752–758. 10.1016/S0022-3476(97)80018-2PubMedCrossRef

66.

Welte R, Postma M, Leidl R, Kretzschmar M: Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005, 32: 474–483. 10.1097/01.olq.0000161181.48687.cfPubMedCrossRef

67.

Pinkerton SD, Holtgrave DR, Johnson-Masotti AP, Turk ME, Hackl KL, DiFranceisco W, NIMH Multisite HIV Prevention Trial Group: Cost-effectiveness of the NIMH multisite HIV prevention intervention. AIDS Behav 2002, 6: 83–96. 10.1023/A:1014532713594CrossRef

68.

Wasserheit JN: Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992, 19: 61–77.PubMedCrossRef

69.

Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, Kagina G, Newell J, Mugeye K, Mabey D, Hayes R: Impact of Improved Treatment of Sexually-Transmitted Diseases on Hiv-Infection in Rural Tanzania - Randomized Controlled Trial. Lancet 1995, 346: 530–536. 10.1016/S0140-6736(95)91380-7PubMedCrossRef

70.

Chesson HW, Pinkerton SD: Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr 2000, 24: 48–56.PubMedCrossRef

71.

Kerani RP, Handsfield HH, Stenger MS, Shafii T, Zick E, Brewer D, Golden MR: Rising rates of syphilis in the era of syphilis elimination. Sex Transm Dis 2007, 34: 154–161. 10.1097/01.olq.0000233709.93891.e5PubMedCrossRef

72.

Buchacz K, Greenberg A, Onorato I, Janssen R: Syphilis epidemics and human immunodeficiency virus (HIV) incidence among men who have sex with men in the United States: implications for HIV prevention. Sex Transm Dis 2005, 32: S73-S79. 10.1097/01.olq.0000180466.62579.4bPubMedCrossRef

73.

Hogben M, Paffel J, Broussard D, Wolf W, Kenney K, Rubin S, George D, Samoff E: Syphilis partner notification with men who have sex with men: a review and commentary. Sex Transm Dis 2005, 32: S43-S47. 10.1097/01.olq.0000180565.54023.bfPubMedCrossRef

74.

Paz-Bailey G, Meyers A, Blank S, Brown J, Rubin S, Braxton J, Zaidi A, Schafzin J, Weigl S, Markowitz LE: A case-control study of syphilis among men who have sex with men in New York City: association with HIV infection. Sex Transm Dis 2004, 31: 581–587.PubMedCrossRef

75.

Taylor M, Aynalem G, Smith L, Bemis C, Kenney K, Kerndt P: Correlates of Internet use to meet sex partners among men who have sex with men diagnosed with early syphilis in Los Angeles County. Sex Transm Dis 2004, 31: 552–556. 10.1097/01.olq.0000137902.71284.b0PubMedCrossRef

76.

Pinkerton SD, Chesson HW, Holtgrave DR, Kassler W, Layde PM: When is an HIV infection prevented and when is it merely delayed? Eval Rev 2000, 24: 251–271.PubMedCrossRef

77.

Truong HHM, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant RM, Louie B, McFarland W: Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect 2006, 82: 461–466. 10.1136/sti.2006.019950PubMedCentralPubMedCrossRef

78.

Varghese B, Peterman TA, Holtgrave DR: Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS 1999, 13: 1745–1751. 10.1097/00002030-199909100-00019PubMedCrossRef

79.

Paltiel AD, Weinstein MC, Kimmel AD, Seage GR III, Losina E, Zhang H, Freedberg KA, Walensky RP: Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med 2005, 352: 586–595. 10.1056/NEJMsa042088PubMedCrossRef

80.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK: Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005, 352: 570–585. 10.1056/NEJMsa042657PubMedCrossRef

81.

Cohen DA, Wu SY, Farley TA: Comparing the cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr 2004, 37: 1404–1414. 10.1097/01.qai.0000123271.76723.96PubMedCrossRef

82.

MacKellar DA, Valleroy LA, Secura GM, Bartholow BN, McFarland W, Shehan D, Ford W, LaLota M, Celentano DD, Koblin BA, Torian LV, Perdue TE, Janssen RS: Repeat HIV testing, risk behaviors, and HIV seroconversion among young men who have sex with men: a call to monitor and improve the practice of prevention. J Acquir Immune Defic Syndr 2002, 29: 76–85.PubMedCrossRef

83.

Centers for Disease Control and Prevention: HIV counseling and testing in publicly funded sites: Annual report 1997 and 1998. Atlanta GA, Centers for Disease Control and Prevention; 2001.

84.

Priddy FH, Pilcher CD, Moore RH, Tambe P, Park MN, Fiscus SA, Feinberg MB, del RC: Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007, 44: 196–202. 10.1097/01.qai.0000254323.86897.36PubMedCrossRef

85.

Blandford JM, Gift TL: Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women. Sex Transm Dis 2006, 33: S117-S121. 10.1097/01.olq.0000235148.64274.2fPubMedCrossRef

86.

Institute of Medicine (Committee on Prevention and Control of Sexually Transmitted Diseases): The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Edited by: Eng TR and Butler WT. Washington, D.C, National Academy Press; 1997.

87.

Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ: Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Medical Decision Making 1985, 5: 157–177. 10.1177/0272989X8500500205PubMedCrossRef

88.

Heffelfinger JD, Swint EB, Berman SM, Weinstock HS: Trends in primary and secondary syphilis among men who have sex with men in the United States. Am J Public Health 2007, 97: 1076–1083. 10.2105/AJPH.2005.070417PubMedCentralPubMedCrossRef

89.

Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S: Births: final data for 2004. Natl Vital Stat Rep 2006, 55: 1–101.

90.

Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, Lindblom B, Herrmann B: Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. Sex Transm Infect 2006, 82: 212–218. 10.1136/sti.2005.017186PubMedCentralPubMedCrossRef

91.

Garnett GP: An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002, 78: 7–12. 10.1136/sti.78.1.7PubMedCentralPubMedCrossRef

92.

Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance, 2005. Atlanta, U.S. Department of Health and Human Services; 2006.

93.

Blocker ME, Levine WC, St Louis ME: HIV prevalence in patients with syphilis, United States. Sex Transm Dis 2000, 27: 53–59. 10.1097/00007435-200001000-00011PubMedCrossRef

94.

Stray-Pedersen B: Economic evaluation of maternal screening to prevent congenital syphilis. Sex Transm Dis 1983, 10: 167–172.PubMedCrossRef

95.

Silberstein GS, Coles FB, Greenberg A, Singer L, Voigt R: Effectiveness and cost-benefit of enhancements to a syphilis screening and treatment program at a county jail. Sex Transm Dis 2000, 27: 508–517. 10.1097/00007435-200010000-00004PubMedCrossRef

Title: Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States
Authors: Harrell W Chesson
Dayne Collins
Kathryn Koski
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Cost Effectiveness and Resource Allocation / Issue 1/2008
Electronic ISSN: 1478-7547
DOI: https://doi.org/10.1186/1478-7547-6-10

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Cost-effectiveness of smoking cessation to prevent age-related macular degeneration

Community-based DOTS and family member DOTS for TB control in Nepal: costs and cost-effectiveness

Could CT screening for lung cancer ever be cost effective in the United Kingdom?

Societal costs of air pollution-related health hazards: A review of methods and results

Is the value of a life or life-year saved context specific? Further evidence from a discrete choice experiment

Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease